Drug Trial Radar · NCT06902844
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Apr 5, 2025
Primary completion
Oct 31, 2027
Study completion Jan 10, 2028
Sponsor
- Lead sponsor
- Tongji HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nanjing IASO Biotechnology Co., Ltd.
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus (SLE)
- Lupus Nephritis (LN)
Interventions
Equecabtagene Autoleucel InjectionDrug
dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate of SRI-4 at 6 months after Eque-cel infusionTime frame: 6 months post Eque-cel infusion.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.